Physician profile
Michael Noble
NPI 1598794976
$903.03
in general payments reported to CMS, 2019-2025
13 companies · $342 in 2025
The $342 reported for 2025 was more than what 78% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.89 · 2021: $14.75 · 2022: $87.39 · 2023: $179 · 2024: $266 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $260.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $250.62 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $105.08 | 2020-2024 | Evenity, Prolia |
| Innovation Technologies INC | $57.34 | 2025 | Irrisept |
| Astrazeneca Pharmaceuticals Lp | $50.86 | 2022-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.55 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $31.54 | 2025 | Cologuard Collection Kit |
| Bioventus LLC | $26.36 | 2024 | Exogen Ultrasound Bone Healing System |
| Pacira Pharmaceuticals Incorporated | $24.55 | 2023 | Iovera, Zilretta |
| Astellas Pharma US INC | $16.60 | 2024 | Veozah |
| Abbvie INC. | $16.26 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.09 | 2023 | Qelbree |
| Novartis Pharmaceuticals Corporation | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Noble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.